The trick with high-yield dividend stocks is that they sound great on the surface, but they can be oh so dangerous … and the high yield could actually be the warning sign.
High dividend yields can often be a product of a severely reduced stock price, and while quick dips can happen on market sentiment, monster gaps down usually happen for a reason.
Hot High Dividend Stocks To Invest In Right Now: Westlake Chemical Corporation(WLK)
Westlake Chemical Corporation manufactures and markets basic chemicals, vinyls, polymers, and fabricated building products. It operates in two segments, Olefins and Vinyls. The Olefins segment provides ethylene, polyethylene, styrene monomer, and various ethylene co-products, such as chemical grade propylene, crude butadiene, pyrolysis gasoline, and hydrogen. The Vinyls segment offers polyvinyl chloride (PVC), vinyl chloride monomer, ethylene dichloride, chlorine, caustic soda, and ethylene. This segment also manufactures and sells products fabricated from PVC, including water, sewer, irrigation, and conduit pipes; window and door profiles; and fences. The company?s products are used in various applications, such as consumer and industrial markets comprising flexible and rigid packaging, automotive products, coatings, and residential and commercial construction, as well as in other durable and non-durable goods. Westlake Chemical Corporation provides its products for chem ical processors, plastics fabricators, construction contractors, municipalities, and supply warehouses in the United States, Canada, Singapore, and internationally. The company was founded in 1985 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Louis Navellier]
To get to the point, here are five companies that have the analyst community buzzing, and they should be on your radar as well.
Facebook (FB): In the past three months, estimates have been revised up 23%. Analysts now expect 47.5% annual sales growth and 58.8% earnings growth this quarter. . Melco Crown Entertainment (MPEL): In the past three months, estimates have been upwardly revised 12%. Analysts now expect 19.9% sales growth and 85% earnings growth. MPEL is a strong buy. Netflix (NFLX): In the past three months, estimates have been upwardly revised 41%. Analysts now expect 23.5% sales growth and 400% earnings growth. NFLX is a strong buy. Westlake Chemical (WLK): In the past three months, estimates have been revised up 13%. Analysts now expect 15.6% sales growth and 50% earnings growth this quarter. . Nu Skin Enterprises (NUS): In the past three months, estimates have been revised up 17%. Analysts now expect 78.1% sales growth and 97.9% earnings growth. NUS is a strong buy.To put these earnings estimates into perspective, analysts forecast that the average S&P 500 company will grow earnings by 8.8% this quarter. This means that each of the five buys above are well-positioned to win this earnings season.
- [By Lisa Levin]
Westlake Chemical (NYSE: WLK) shares fell 0.25% to touch a new 52-week low of $67.41. Westlake Chemical's PEG ratio is 4.40.
HSBC Holdings plc (NYSE: HSBC) shares declined 0.59% to reach a new 52-week low of $49.54. Analysts at Credit Suisse downgraded the stock from Outperform to Underperform.
- [By Robert Rapier]
Westlake Chemical Partners�(expected ticker WLKP) was recently formed by�Westlake Chemical�(NYSE: WLK) to operate, acquire and develop ethylene production facilities and related assets. WLK is a manufacturer and supplier of petrochemicals, vinyls, polymers and building products produced at 16 plants across North America and one in China.
Hot High Dividend Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.
Advisors' Opinion:- [By George Budwell]
Will BioMarin be the next orphan drugmaker to be bought out?
Over the last decade, BioMarin Pharmaceutical (NASDAQ: BMRN ) has become one of the top orphan drug specialists, making it a frequent visitor to the buyout rumor mill. Roche (NASDAQOTH: RHHBY ) was previously named as an interested party, but the company's CEO squashed that rumor, saying BioMarin was too expensive. - [By Ben Levisohn]
Sure Intercept Pharmaceuticals (ICPT) might feel like the only biotech stock that matters today, but there are others. For instance, Incyte (INCY) and� BioMarin (BMRN) are on the move after Barclays changed its ratings on the pair.
- [By Nick Taborek]
BioMarin Pharmaceutical Inc. (BMRN) rallied 3.2 percent to $79.99. Roche Holding AG, the world�� biggest maker of cancer drugs, is lining up as much as $15 billion in debt financing to buy Novato, California-based BioMarin, DealReporter reported, citing people familiar with the situation.
Hot Beverage Stocks To Watch Right Now: EveryWare Global Inc (EVRY)
EveryWare Global, Inc., formerly ROI Acquisition Corp., incorporated on September 19, 2011, is the designer and seller of tabletop and food preparation products for the consumer and foodservice markets. The Company�� global platform allows the Company to market and distribute internationally its total portfolio of products, including flatware, dinnerware, crystal stemware, glassware, serveware, cutlery, buffetware, candle glass, floral glass, spirit bottles, kitchen tools and gadgets and kitchen accessories. On June 18, 2013, the Company acquired the George Wilkinson and Samuel Groves business units of Metalrax Housewares, a maker and provider of metal bakeware, cooking utensils and catering supplies.
The Company also licenses the trademarks and distributes the Stolzle, Schonwald, Strata and BuffetEuro branded products in its Consumer, Foodservice and International segments. The Company operates in the United States, Canada, Mexico, Latin America, Europe and Asia.
Advisors' Opinion:- [By John Udovich]
On Wednesday, small cap kitchen stock Everyware Global Inc (NASDAQ: EVRY) surged 52.94% after announcing an amendment to extend its forbearance agreement with lenders until July 15 that could give the company�time to find a long-term financing solution���meanings its worth taking as closer look at the stock along with potential peers Libbey Inc (NYSEMKT: LBY) and Lifetime Brands Inc (NASDAQ: LCUT).
Hot High Dividend Stocks To Invest In Right Now: Trovagene Inc (TROV)
TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.
On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.
In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).
Advisors' Opinion:- [By David Goodboy]
Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).
- [By Daniel Lauchheimer]
In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.
Hot High Dividend Stocks To Invest In Right Now: Forestar Group Inc (FOR)
Forestar Group Inc. (Forestar) is a real estate and natural resources company. The Company owns directly or through ventures almost 147,000 acres of real estate located in nine states and 12 markets and about 595,000 net acres of mineral interests. As of December 31, 2011, the Company had approximately 131,000 acres of timber on its 147,000 real estate acres and about 17,000 acres of timber under lease. During the year ended December 31, 2011, the Company generated revenues of $136 million. It operates in three segments: Real estate, Mineral resources and Fiber resources. Its real estate segment generated 78% of its 2011 consolidated revenues. The Company sells wood fiber from portions of its land, primarily in Georgia, and lease land for recreational uses. It leases its mineral interests to third parties for the exploration and production of oil and natural gas, principally in Texas and Louisiana. On January 20, 2012, it sold its 25% interest in Palisades West LLC to Dimensional Fund Advisors L.P. In September 2012, the Company acquired CREDO Petroleum Corp.
Real estate
In the Company�� real estate segment, it conducts an array of project planning and management activities related to the acquisition, entitlement, development and sale of real estate, primarily residential and mixed-use communities. It owns and manages its projects either directly or through ventures. Its development projects are principally located in the markets of Texas. The Company has over 16,000 acres entitled, developed and under development, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. In 2011, it sold over 17,000 acres of undeveloped land through its retail land sales program. In addition, it sold 112 entitled acres from two residential projects. The majority of its projects are single-family residential and mixed-use communities. During 2011, the Company acquired 180 substantially completed residential lots in Houston, Texas; three multifamily develo! pment sites located in Austin, Denver, and Dallas.
The Company develops lots for single-family homes and develops multifamily properties on its commercial tracts or other developed sites it may purchase. In addition, the Company sells commercial tracts that are ready for construction of buildings for retail, office, industrial or other commercial uses. It sells residential lots primarily to national and regional homebuilders and, to a lesser extent, local homebuilders. The Company has 75 entitled, developed or under development projects in seven states and 11 markets, principally in the markets of Texas, encompassing over 16,000 remaining acres, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. It also markets and sells undeveloped land through its retail sales program.
Commercial tracts are developed internally or sold to or ventured with commercial developers that specialize in the construction and operation of income producing properties, such as apartments, retail centers, or office buildings. The Company also sells land designated for commercial use to regional and local commercial developers. It has about 2,500 acres of entitled land designated for commercial use. Cibolo Canyons is a mixed-use project in the San Antonio market area.
Mineral Resources
The Company owns mineral interests beneath approximately 595,000 net acres located in the United States, principally in Texas, Louisiana, Georgia and Alabama. It is engaged in leasing certain portions of these mineral interests to third parties for the exploration and production of oil and natural gas. Of the Company�� 595,000 net acres of mineral interests, about 515,000 net acres are available for lease. It has about 80,000 net acres leased for oil and natural gas exploration activities, of which about 32,000 net acres are held by production from over 530 oil and natural gas wells that are operated by others. During 2011, the Company acquired unproved le! asehold p! roperties associated with 13,000 net mineral acres in Alabama and Georgia.
The Company has about 251,000 net mineral acres in East Texas and about 144,000 net mineral acres in Louisiana located within the East Texas and Gulf Coast Basins. It has mineral interests in and around production trends in the Wilcox, Frio, Cockfield, James Lime, Pettet, Travis Peak, Cotton Valley, Austin Chalk, Haynesville Shale and Bossier formations. The Company has about 1,000 net mineral acres in the Fort Worth Basin. It also has mineral interests in and around the Barnett Shale. The Company has about 40,000 net mineral acres in Alabama and about 157,000 net mineral acres in Georgia. The Company did not drill any wells in 2011.
Fiber Resources
The Company has about 131,000 acres of timber it owns directly or through ventures and about 17,000 acres of timber under lease. In 2011, it sold to Temple-Inland, over 323,000 tons of timber from its lands. During 2011, about 131,000 acres of its land, primarily in Georgia, were leased for recreational purposes. During 2011, the Company sold 57,000 acres of timberland in Georgia, Alabama, and Texas.
Advisors' Opinion:- [By Andy Batts]
The shares of Forestar Group (FOR) are trading at ~30% discount to the company's NAV. The company operates in three business segments: real estate, oil and gas, and other natural resources. Forestar has a rich portfolio of assets and businesses, including 133,000 acres of real estate; 752,000 acres of oil and gas properties; 1.5 million acres of water rights; and 275,000 acres of timberland.
No comments:
Post a Comment